Explain the principal of drug action Describe consequences of drug metabolism How can we increase the renal elimination of drugs during toxicity
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
I now have sufficient information from the textbooks to provide a comprehensive answer. Let me compile it.
Pharmacology: Drug Action, Drug Metabolism, and Renal Elimination
1. Principles of Drug Action
Drug action is the interaction between a drug molecule and a biological target that ultimately produces a pharmacological effect. This can be broken down into several foundational principles.
A. Drug–Receptor Interaction
Most drugs act by binding to specific receptors — macromolecular proteins on cell surfaces or within cells. The binding is governed by the complementarity of the drug's shape, charge, and chemical properties to the receptor's binding site — analogous to a key fitting a lock.
Three major bond types mediate drug–receptor interactions:
- Covalent bonds — very strong, often irreversible (e.g., aspirin irreversibly acetylates cyclooxygenase; its effect on platelets lasts days)
- Electrostatic bonds — the most common type, including ionic bonds, hydrogen bonds, and van der Waals forces; weaker and reversible
- Hydrophobic bonds — weak interactions important for lipid-soluble drugs
"Drugs that bind through weak bonds to their receptors are generally more selective than drugs that bind by means of very strong bonds. This is because weak bonds require a very precise fit of the drug to its receptor." — Katzung's Basic and Clinical Pharmacology, 16th Edition
B. Drug–Receptor Models: Agonists, Partial Agonists & Antagonists
Receptors exist in two conformational states: inactive (R) and active (R*). Even without a drug, a small fraction exists in the active form — termed constitutive or basal activity.
| Drug Type | Mechanism | Effect |
|---|---|---|
| Full agonist | High affinity for R* (active state); stabilizes it | Maximum response |
| Partial agonist | Intermediate affinity for both states | Submaximal response regardless of dose; can antagonize full agonists |
| Antagonist | Equal affinity for R and R*; occupies receptor without changing ratio | No intrinsic effect; blocks agonist access |
| Inverse agonist | High affinity for R (inactive state); reduces constitutive activity | Effect opposite to agonist |
Competitive antagonism: reversible; increasing agonist concentration can overcome it (parallel rightward shift of dose-response curve).
Physiologic antagonism: occurs between endogenous systems (e.g., glucocorticoids raise blood glucose, which is opposed by insulin) — less specific and harder to control than receptor-specific antagonism.
C. Transmembrane Signaling Mechanisms
Five major mechanisms carry chemical information across cell membranes:
- Lipid-soluble ligands cross the membrane and act on intracellular receptors (e.g., steroid hormones acting on nuclear transcription factors)
- Transmembrane receptor proteins with intrinsic enzymatic activity allosterically activated by extracellular ligand (e.g., receptor tyrosine kinases)
- Transmembrane receptors that recruit and activate separate intracellular protein tyrosine kinases (e.g., cytokine receptors → JAK-STAT pathway)
- Ligand-gated ion channels — opened or closed by ligand binding (e.g., nicotinic acetylcholine receptor, GABA-A receptor)
- G protein–coupled receptors (GPCRs) — ligand activates a GTP-binding protein → modulates intracellular second messengers (cAMP, IP₃, DAG, Ca²⁺)
"Most transmembrane signaling is accomplished by a small number of different molecular mechanisms... adapted through the evolution of distinctive protein families to transduce many different signals." — Katzung's Basic and Clinical Pharmacology, 16th Edition
D. Non-Receptor Mechanisms
Some drugs act without binding classical receptors:
- Enzyme inhibition (e.g., ACE inhibitors, statins inhibiting HMG-CoA reductase)
- Ion channel blockade (e.g., local anesthetics blocking Na⁺ channels)
- Physicochemical mechanisms (e.g., antacids neutralizing gastric acid; mannitol increasing osmolality)
- Transport protein inhibition (e.g., SSRIs blocking the serotonin transporter)
E. Dose–Effect Relationship
The relationship between drug concentration and pharmacological effect is described by the pharmacodynamic component: maximum response (E_max) and the concentration producing 50% of maximum effect (EC₅₀ or C₅₀). Pharmacokinetics (input, distribution, elimination) determine how much drug reaches its target and for how long.
2. Consequences of Drug Metabolism
Drug metabolism (biotransformation) occurs predominantly in the liver, but also in the kidney, intestinal epithelium, lung, and plasma. It transforms drugs into compounds that are generally more polar and more readily excreted. There are two phases:
Phase I Metabolism
- Chemical modification — most often oxidation by the cytochrome P450 (CYP) monooxygenase superfamily (CYP3A4, CYP2D6, CYP2C9, CYP2C19, CYP2B6)
- Also includes reduction and hydrolysis
- Introduces or unmasks a functional group (–OH, –NH₂, –SH)
Phase II Metabolism
- Conjugation of endogenous molecules to the drug or its Phase I metabolite
- Enzymes: glucuronyl-, acetyl-, sulfo-, and methyltransferases
- Products (glucuronides, sulfates, etc.) are highly polar and readily excreted
Key Consequences
| Consequence | Explanation | Example |
|---|---|---|
| Inactivation of active drug | Most common outcome — metabolite is pharmacologically inactive, drug is eliminated | Most benzodiazepines |
| Active metabolite formation | Metabolite retains or gains pharmacological activity | Codeine → morphine (CYP2D6); diazepam → desmethyldiazepam |
| Prodrug activation | Parent drug is inactive; metabolism generates the active form | Clopidogrel → active thienopyridine (CYP2C19); enalapril → enalaprilat |
| Toxic metabolite formation | Metabolite is more harmful than parent drug | Paracetamol (acetaminophen) → NAPQI (N-acetyl-p-benzoquinone imine) — hepatotoxic when glutathione depleted |
| Reduced oral bioavailability (first-pass effect) | Extensive presystemic metabolism prevents effective oral administration | Nitroglycerin cannot be given orally; lignocaine is administered IV |
| Drug interactions | CYP enzyme inhibition or induction by one drug alters metabolism of another | Ketoconazole inhibits CYP3A4 → raises cyclosporine levels; rifampicin induces CYP3A4 → reduces efficacy of many drugs |
| Pharmacogenetic variability | Polymorphisms in CYP genes create poor vs. ultra-rapid metabolizers | CYP2D6 poor metabolizers accumulate codeine or tricyclics; ultra-rapid metabolizers may fail therapy |
| Delayed onset of action | Slow accumulation of active metabolites | Slow accumulation of desmethyldiazepam |
| Prolonged drug effect | Active metabolite has longer half-life than parent drug | Nordiazepam persists after diazepam is cleared |
"Drug metabolites may exert important pharmacologic activity... Some drugs undergo near-complete presystemic metabolism and thus cannot be administered orally." — Harrison's Principles of Internal Medicine, 22nd Edition
3. Increasing Renal Elimination of Drugs During Toxicity
The kidney eliminates drugs through three processes: glomerular filtration, proximal tubular secretion, and distal tubular reabsorption. Enhancing renal elimination in overdose/toxicity exploits these mechanisms:
A. Urinary pH Manipulation (Ion Trapping)
This is the most clinically important technique. Drug movement across tubular epithelium depends on the ionized fraction — ionized drugs are polar and cannot diffuse back into the systemic circulation.
Principle: Adjust urine pH so the drug is kept in its ionized form in the tubular lumen → prevents reabsorption → increases elimination.
| Drug Property | Manipulation | Method | Example |
|---|---|---|---|
| Weak acid (pKa 3–8) | Alkalinize urine | IV sodium bicarbonate (NaHCO₃) | Phenobarbital, salicylates (aspirin) overdose |
| Weak base (pKa 6–12) | Acidify urine (less commonly used) | Ammonium chloride or ascorbic acid | Amphetamine, phencyclidine (rarely done due to risks) |
"Weak acids can be eliminated by alkalinization of the urine, whereas elimination of weak bases may be increased by acidification of the urine. This process is called 'ion trapping.' For example, a patient presenting with phenobarbital (weak acid) overdose can be given bicarbonate, which alkalinizes the urine and keeps the drug ionized, thereby decreasing its reabsorption." — Lippincott Illustrated Reviews: Pharmacology
Clinical note: Urine acidification is rarely used today because metabolic acidosis and worsening of myoglobinuria-associated renal injury outweigh the benefits.
B. Forced Diuresis / Volume Expansion
- Increasing urine flow rate (with IV fluids ± diuretics such as furosemide) increases tubular flow, reducing the time for passive reabsorption and diluting the drug concentration in the tubular lumen
- Most effective when combined with pH manipulation
- Must be used cautiously to avoid pulmonary oedema or electrolyte disturbance
C. Renal Replacement Therapy (Dialysis/Haemofiltration)
For drugs that cannot be adequately eliminated by manipulation alone:
- Haemodialysis: effective for small molecules with low volume of distribution (Vd), low protein binding, and water solubility (e.g., lithium, salicylates, methanol, ethylene glycol, metformin)
- Haemofiltration (CVVH): better for larger or less dialyzable molecules
- Peritoneal dialysis: less efficient, rarely used for acute toxicity
Drugs with high Vd (extensively tissue-bound, e.g., tricyclic antidepressants, digoxin) are not effectively dialyzed because only the small plasma fraction is accessible.
D. Reducing Protein Binding
Since only free (unbound) drug is filtered at the glomerulus, displacing a drug from plasma proteins theoretically increases the filterable fraction. This is rarely exploited clinically as the displaced drug also redistributes to tissues.
E. Inhibiting Tubular Reabsorption Transporters
Experimental/investigational — drugs that inhibit renal reabsorption transporters (e.g., P-glycoprotein inhibitors) can increase urinary drug excretion. Not yet standard clinical practice.
Summary: Approach to Enhancing Renal Elimination in Toxicity
Drug overdose → assess:
│
├── Water-soluble, small molecule, low Vd, low protein binding?
│ → Consider haemodialysis (e.g., lithium, salicylates)
│
├── Weak acid? (salicylates, phenobarbital)
│ → IV NaHCO₃ → alkaline urine → ion trapping → ↑ excretion
│
├── Weak base? (amphetamine, rarely)
│ → Urine acidification (rarely done, risk>benefit in most cases)
│
└── General → IV fluids for forced diuresis (with caution)
Sources: Katzung's Basic and Clinical Pharmacology, 16th Edition; Lippincott Illustrated Reviews: Pharmacology; Harrison's Principles of Internal Medicine, 22nd Edition; Barash, Cullen, and Stoelting's Clinical Anesthesia, 9th Edition
Where’s the answer?
The full answer was provided in my previous response. Here it is again in full:
Pharmacology: Drug Action, Drug Metabolism, and Renal Elimination
1. Principles of Drug Action
Drug action is the interaction between a drug molecule and a biological target that produces a pharmacological effect, governed by several foundational principles.
A. Drug–Receptor Interaction
Most drugs act by binding to specific receptors — macromolecular proteins on cell surfaces or within cells. Binding depends on the complementarity of the drug's shape, charge, and chemical properties to the receptor's binding site.
Three major bond types mediate drug–receptor interactions:
- Covalent bonds — very strong, often irreversible (e.g., aspirin irreversibly acetylates cyclooxygenase; its antiplatelet effect lasts days)
- Electrostatic bonds — most common; includes ionic, hydrogen bonds, van der Waals forces; weaker and reversible
- Hydrophobic bonds — weak; important for lipid-soluble drugs interacting with membrane lipids
"Drugs that bind through weak bonds to their receptors are generally more selective... because weak bonds require a very precise fit of the drug to its receptor." — Katzung's Basic and Clinical Pharmacology, 16th Ed.
B. Agonists, Partial Agonists & Antagonists
Receptors exist in two conformational states: inactive (R) and active (R*). Even without a drug, a small fraction exists in the active state — this is constitutive/basal activity.
| Drug Type | Mechanism | Effect |
|---|---|---|
| Full agonist | High affinity for R* (active state); stabilizes it | Maximum response |
| Partial agonist | Intermediate affinity for both states | Submaximal response; can also block full agonists |
| Competitive antagonist | Binds receptor reversibly; blocks agonist access | No intrinsic effect; shifts dose-response curve rightward |
| Inverse agonist | High affinity for R (inactive state) | Reduces constitutive activity; effect opposite to agonist |
Physiologic antagonism: two drugs with opposing effects via different receptors (e.g., glucocorticoids raise blood glucose; insulin opposes this). Less specific and harder to control than receptor-specific antagonism.
C. Transmembrane Signaling Mechanisms
Five major strategies carry chemical signals across the plasma membrane:
- Lipid-soluble ligands cross the membrane → act on intracellular receptors (e.g., steroid hormones activating nuclear transcription factors)
- Transmembrane receptor proteins with intrinsic enzymatic (tyrosine kinase) activity, allosterically activated by an extracellular ligand (e.g., insulin receptor)
- Transmembrane receptors that recruit and activate separate intracellular protein tyrosine kinases (e.g., cytokine receptors → JAK-STAT)
- Ligand-gated ion channels — directly opened or closed by ligand binding (e.g., nicotinic ACh receptor, GABA-A receptor)
- G protein–coupled receptors (GPCRs) — ligand activates a GTP-binding (G) protein → modulates second messengers (cAMP, IP₃, DAG, Ca²⁺)
D. Non-Receptor Mechanisms
Some drugs act without classical receptor binding:
- Enzyme inhibition — ACE inhibitors, statins (HMG-CoA reductase)
- Ion channel blockade — local anesthetics (Na⁺ channels)
- Physicochemical — antacids (neutralize HCl), mannitol (osmotic effect)
- Transport inhibition — SSRIs (block serotonin reuptake transporter)
E. Dose–Effect Relationship
Pharmacodynamics governs the concentration–effect relationship (E_max, EC₅₀). Pharmacokinetics (absorption, distribution, metabolism, elimination) determines how much drug reaches the target and for how long. Together, they define the rational basis for dosing.
2. Consequences of Drug Metabolism
Metabolism (biotransformation) occurs mainly in the liver (also kidney, intestinal epithelium, lung, plasma). It converts drugs into compounds that are generally more polar and more readily excreted.
Phase I
Chemical modification — predominantly oxidation by cytochrome P450 (CYP) enzymes (CYP3A4, CYP2D6, CYP2C9, CYP2C19, CYP2B6). Also includes reduction and hydrolysis. Introduces or unmasks a functional group.
Phase II
Conjugation of endogenous molecules (glucuronate, sulfate, acetyl, methyl) to the drug or Phase I metabolite → highly polar, easily excreted products.
Key Consequences
| Consequence | Explanation | Clinical Example |
|---|---|---|
| Drug inactivation | Metabolite is pharmacologically inactive → drug eliminated | Most benzodiazepines |
| Active metabolite formation | Metabolite retains or gains activity | Codeine → morphine (CYP2D6); diazepam → desmethyldiazepam |
| Prodrug activation | Parent drug is inactive; metabolism generates active form | Clopidogrel → active thienopyridine; enalapril → enalaprilat |
| Toxic metabolite formation | Metabolite is more toxic than parent drug | Paracetamol → NAPQI (hepatotoxic when glutathione depleted) |
| First-pass effect / reduced bioavailability | Extensive presystemic metabolism prevents oral use | Nitroglycerin, lignocaine — must be given parenterally |
| Drug–drug interactions | CYP induction or inhibition alters another drug's level | Ketoconazole (CYP3A4 inhibitor) ↑ cyclosporine; rifampicin (inducer) ↓ OCP efficacy |
| Pharmacogenetic variability | CYP polymorphisms → poor vs. ultra-rapid metabolizers | CYP2D6 poor metabolizers: codeine toxicity; ultra-rapid: treatment failure |
| Prolonged effect | Active metabolite has longer half-life than parent | Nordiazepam persists well after diazepam is cleared |
| Delayed onset | Slow accumulation of active metabolite | Clopidogrel's antiplatelet effect takes time despite short plasma t½ |
"Drug metabolites may exert important pharmacologic activity... Some drugs undergo near-complete presystemic metabolism and thus cannot be administered orally." — Harrison's Principles of Internal Medicine, 22nd Ed.
3. Increasing Renal Elimination of Drugs During Toxicity
The kidney handles drugs via glomerular filtration, proximal tubular secretion, and distal tubular reabsorption. In overdose/toxicity, the goal is to maximize excretion and minimize reabsorption.
A. Urinary pH Manipulation — Ion Trapping (Most important)
Ionized (charged) drug cannot diffuse back across the tubular epithelium. By adjusting urine pH, the drug is kept ionized in the tubular lumen → cannot be reabsorbed → excreted.
| Drug Type | Strategy | Agent | Example |
|---|---|---|---|
| Weak acid (pKa 3–8) | Alkalinize urine (pH > 7.5) | IV sodium bicarbonate (NaHCO₃) | Salicylate (aspirin), phenobarbital overdose |
| Weak base (pKa 6–12) | Acidify urine | Ammonium chloride (rarely used) | Amphetamine, phencyclidine |
"A patient presenting with phenobarbital (weak acid) overdose can be given bicarbonate, which alkalinizes the urine and keeps the drug ionized, thereby decreasing its reabsorption." — Lippincott Illustrated Reviews: Pharmacology
Note: Urine acidification is largely abandoned in modern practice due to risks of metabolic acidosis and worsening of rhabdomyolysis-associated renal injury.
B. Forced Diuresis / Volume Expansion
- IV fluids ± loop diuretics (furosemide) increase urine flow
- Reduces contact time in the tubule → less passive reabsorption
- Most effective when combined with pH manipulation
- Risk: fluid overload, electrolyte disturbance — requires monitoring
C. Renal Replacement Therapy (Dialysis)
For drugs that cannot be eliminated by the above methods:
| Modality | Best Suited For | Examples |
|---|---|---|
| Haemodialysis | Small molecules, low Vd, low protein binding, water-soluble | Lithium, salicylates, methanol, ethylene glycol, metformin |
| Haemofiltration (CVVH) | Larger or less dialyzable molecules; haemodynamically unstable patients | Extended use in ICU settings |
| Peritoneal dialysis | Less efficient; rarely used for acute poisoning | — |
Drugs NOT effectively dialyzed: those with high volume of distribution (Vd) (extensively tissue-bound) — e.g., tricyclic antidepressants, digoxin. Only the small plasma-circulating fraction is accessible to dialysis.
D. Reducing Protein Binding
Only free (unbound) drug is filtered at the glomerulus. In theory, displacing drug from albumin increases the filterable fraction — but displaced drug also redistributes to tissues, limiting practical benefit. Not a primary clinical strategy.
Summary Approach
Drug overdose → assess drug properties:
├── Small molecule, water-soluble, low Vd, low protein binding?
│ → Haemodialysis (lithium, salicylates, methanol)
│
├── Weak ACID? (salicylates, phenobarbital)
│ → IV NaHCO₃ → alkaline urine (pH ≥ 7.5) → ion trapping → ↑ excretion
│
├── Weak BASE? (amphetamine)
│ → Urine acidification (rarely done today — risk > benefit)
│
└── All cases → IV fluids for forced diuresis (monitor fluid balance)
Sources: Katzung's Basic and Clinical Pharmacology, 16th Ed. | Lippincott Illustrated Reviews: Pharmacology | Harrison's Principles of Internal Medicine, 22nd Ed. | Barash, Cullen, and Stoelting's Clinical Anesthesia, 9th Ed.
